ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO1117

Safety and Efficacy of ADV7103, an Innovative Prolonged-Release Oral Alkalising Combination Product, after 6-Months of Treatment in Distal Renal Tubular Acidosis (dRTA) Patients

Session Information

Category: Fluid, Electrolytes, and Acid-Base

  • 704 Fluid, Electrolyte, Acid-Base Disorders

Authors

  • Bertholet-Thomas, Aurélia, Centre de référence des maladies rénales rares, Bron, France
  • Guittet, Catherine, Advicenne, Nîmes, France
  • Manso, Maria Asuncion, Advicenne, Nîmes, France
  • Granier, Luc andre, Advicenne, Nîmes, France

Group or Team Name

  • B22CS study investigators
Background

A new innovative age-adapted prolonged-release granule combination of potassium citrate and potassium bicarbonate, ADV7103, has been developed in order to achieve sustained physiological blood pH values in dRTA patients with a simplified dosing regimen . The current standards of care (SoC) require multiple administrations and are not always well tolerated.
The objective of this clinical study was to assess safety of ADV7103 after treatment for 6 months as well as to follow-up bicarbonate levels and evaluate patient’s satisfaction.

Methods

Adult and pediatric dRTA patients (N=30) were included in a multicentre (N=12), open-label, 24-month study. They received ADV7103 twice a day at appropriate doses.
Preliminary data after 6 months of treatment were analysed, including adverse events and bicarbonataemia. Improvement of quality of life was evaluated at by patients and/or their parents using a 100-mm visual analogue scale.

Results

A total of 17 patients presented adverse events. Among the 45 adverse events observed, 40 were unrelated, 1 (abdominal pain) was unlikely related, 3 (alopecia, dyspepsia and abdominal pain) were possibly related, and 1 (diarrhea) was probably related to the treatment. The 5 latter adverse events were all of mild intensity. There was only one serious adverse event unrelated to the product (wisdom teeth removal).
Efficacy was maintained after 6 months treatment, with blood bicarbonate levels above 21 mM in 79% of the patients. Only three patients presented bicarbonatemia levels below 20 mM. ADV7103 doses ranged from 1.3 to 7.2 mEq/kg/day.
Patients and/or their parents were extremely satisfied with ADV7103. The change of alkalising treatment from the their SoC to ADV7103 allowed an average improvement of their quality of life of 80.5%, ranging from 76 to 98% depending of the age group considered.

Conclusion

The present preliminary results confirm the excellent safety and efficacy of ADV7103, a combination product allowing treatment with only 2-daily doses. The level of satisfaction of the patients is very high and clinicians are expecting registration of the product for first-line treatment of dRTA.

Funding

  • Private Foundation Support